Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.74 |
| ▸ | MITF | O75030 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | GFER | P55789 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | APP | P05067 | 9/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596886 | 0.87 | SMN1; SMN2 (0.74) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL15948135 | 0.86 | KDM4E (0.76) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL14415813 | 0.85 | KDM4E (0.80) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL8531346 | 0.85 | KDM4E (1.00) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL10032120 | 0.84 | APP (0.63) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL7604821 | 0.84 | NPC1 (0.61) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL14156910 | 0.82 | APP (0.67) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL12392453 | 0.82 | KDM4E (0.74) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL15946338 | 0.81 | KDM4E (0.69) | KDM4EMAPTNPC1RAB9AGAA | |
| SCHEMBL212263 | 0.81 | CYP2C9 (0.71) | KDM4EMAPTNPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147798-B2 | baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment; imaging the patient | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2012-04-03 | — | — | US | disclosed |
| US-7854920-B2 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080305040-A1 | In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein | UNIVERSITY OF PITTSBURGH | 2008-12-11 | — | — | US | disclosed |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | UNIVERSITY OF PITTSBURGH | 2008-09-11 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | APOL1, APOB, APP | KDM4E 3482/4885MAPT 6/4885NPC1 30/4885 |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | TTR, APP, SAAL1 | KDM4E 4740/4885MAPT 14/4885NPC1 332/4885 |
| US-20080286202-A1 | Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition | PSEN2, PSEN1, APP | KDM4E 4792/4885MAPT 13/4885NPC1 109/4885 |
| US-20080305040-A1 | In Vivo or in Vitro Method For Detecting Amyloid Deposits Having at Least One Amyloidogenic Protein | TTR, APBA1, APP | KDM4E 4675/4885MAPT 214/4885NPC1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.